or Try an Advanced Search...

    Technical Analysis for BYSI - BeyondSpring, Inc.

    Grade Last Price % Change Price Change
    C 2.47 2.92% 0.07
    BYSI closed up 2.92 percent on Monday, July 1, 2024, on 40 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical BYSI trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 2.92%
    50 DMA Resistance Bearish 2.92%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.92%
    Outside Day Range Expansion 2.92%
    20 DMA Resistance Bearish 0.41%
    50 DMA Resistance Bearish 0.41%
    50 DMA Resistance Bearish 1.23%
    NR7 Range Contraction 1.23%
    Narrow Range Bar Range Contraction 1.23%
    Inside Day Range Contraction 1.23%
    Older End-of-Day Signals for BYSI ...

       Recent Intraday Alerts

    Alert Time
    Up 1% about 10 hours ago
    60 Minute Opening Range Breakdown 3 days ago
    Down 2 % 3 days ago
    Down 1% 3 days ago
    Rose Above Previous Day's High 3 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    BYSI Chart by TradingView
    Basic chart:

    Profile

    BeyondSpring, Inc. Description

    BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Clinical Medicine Cancer Treatment Chemotherapy Antineoplastic Drugs Small Cell Lung Cancer Cancer Therapies Organic Chemistry NSCLC Protein Kinase Advanced Non Small Cell Lung Cancer Buparlisib Docetaxel Neutropenia

    Is BYSI a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 12 BeyondSpring files to offer up to 10M ordinary shares
    May 22 BeyondSpring (NASDAQ:BYSI) shareholders have earned a 141% return over the last year
    May 3 BeyondSpring To Host Virtual R&D Day to Discuss New Plinabulin Development Strategy for Cancer and Updates for SEED Therapeutics
    Apr 30 BeyondSpring GAAP EPS of -$0.54, revenue of $1.75M
    Apr 29 BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results
    Apr 29 BeyondSpring Files 2023 Annual Report on Form 20-F
    Mar 25 BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
    Mar 6 Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded
    Feb 26 BeyondSpring regains Nasdaq compliance as price surges above $1
    Feb 26 BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
    See more BYSI news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.0
    52 Week Low 0.6534
    Average Volume 61,165
    200-Day Moving Average 1.65
    50-Day Moving Average 2.50
    20-Day Moving Average 2.50
    10-Day Moving Average 2.54
    Average True Range 0.26
    RSI (14) 48.19
    ADX 13.82
    +DI 19.89
    -DI 20.56
    Chandelier Exit (Long, 3 ATRs) 2.21
    Chandelier Exit (Short, 3 ATRs) 3.02
    Upper Bollinger Bands 2.81
    Lower Bollinger Band 2.20
    Percent B (%b) 0.44
    BandWidth 24.13
    MACD Line -0.03
    MACD Signal Line -0.01
    MACD Histogram -0.0172
    Fundamentals Value
    Market Cap 96.37 Million
    Num Shares 39 Million
    EPS -0.71
    Price-to-Earnings (P/E) Ratio -3.48
    Price-to-Sales 35.99
    Price-to-Book 5.38
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.76
    Resistance 3 (R3) 2.72 2.60 2.71
    Resistance 2 (R2) 2.60 2.52 2.61 2.69
    Resistance 1 (R1) 2.53 2.48 2.57 2.57 2.68
    Pivot Point 2.41 2.41 2.42 2.42 2.41
    Support 1 (S1) 2.34 2.33 2.38 2.38 2.26
    Support 2 (S2) 2.22 2.29 2.23 2.25
    Support 3 (S3) 2.15 2.22 2.23
    Support 4 (S4) 2.19